Lung Cancer, Radon and New Strategies

Wallace Akerley Oct 24, 2022

> HEALTH UNIVERSITY OF UTAH



Outline

- Dramatic Evolution of Lung Cancer Understanding
 - Precision Medicine, Genetics and Immunology
 - New Diagnosis and Treatment (many types of lung cancer)
 - Smoker and non-smoker
- Radon-induced Lung Cancer
 - What we do and don't understand
- Strategies to merge and extend new diagnostics
 Clinically identify Radon Induced Lung Cancer



Radon-induced Lung Cancer

- Radon is Radiation
- Lung cancer is the reason we identify + mitigate radon
 - Smoking
 - Avoid asbestos, radiation, heavy metals, etc
- Statistics are real people
- Those involved in Awareness/Mitigation save lives





Invisible Ribbon



Lung Cancer – Unrecognized


- Invisible Killer
- Number 1 Cancer Mortality in the USA
- Lacks Advocacy (lethality)
- Guilt (Tobacco)

ALCASE



USA Cancer Mortality


PEAK



#1 Cause of cancer death (nationally and Utah)

- Improving Mortality Trend
- Has the potential to be a rare cancer again













FIGURE 1. Annual adult per capita cigarette consumption and major smoking and health events — United States, 1900–1998



Sources: United States Department of Agriculture; 1986 Surgeon General's Report.

Lung Cancer









Smoking

Radon




HUNTSMAN





Non-Smoke

Example of Low Smoke State (Utah)





CDC: BRFSS 2010

MMWR / May 31, 2013 / Vol. 62

)-12.9 (2 States) 13.0-15.9 (4 States)

6.0-18.9 (18 States)

19.0-21.9 (16 States)

22.0-24.9 (8 States) 25.0+ (3 States) No data available (3 States)


Utah Lung Cancer Mortality compared to USA

Melanoma of the Skin		30%
Prostate		13%
Brain and Other Nervous System		2%
Myeloma		0%
Non-Hodgkin Lymphoma	-5%	
Leukemia	-6%	
Ovary	-6%	
Breast	-6%	
Kidney and Renal Pelvis	-15%	
Pancreas	-17%	
Urinary Bladder	-18%	
Corpus and Uterus, NOS	-21%	
Colon and Rectum	-24%	
Esophagus	-35%	
Lung and Bronchus	-57%	
All Cancer	-26%	
-100	0% -75% -50% -25% 0%	% 25% 50% 75% 100%
	Percent Above or Below	



Harrell et al. Utah Cancer Registry, 2014.


Utah Cancer Incidence and Mortality





Millar et al. Utah Cancer Registry, 2019.

Clinical Carcinogenesis-What are the failings that let cancer happen?





Cancer Treatment Revolution

Past


- Non-small Cell Lung Cancer One Group
- Organ based Therapy (chemotherapy)

Present (PRECISION MEDICINE)


- NSCLC Many types
- Defined by Histology, Genetics and Immune Profiles
 - Tissue and Blood Profiling
- Precision Medicine (treat based on cancer weakness)
 - Gene Targeted therapy (EGFR, ALK, BRAF, HER2, ROS, RET, MET, NTREK, KRAS)
 - Plasticity Serial Biopsy
- Immunotherapy
 - Biomarker (PD1, PD-L1, Mutational Burden)



NSCLC Treatment




Frequency of Potential Actionable Driver Mutations in NSCLC






Immune checkpoint Regulation






Keynote 024- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic NSCLC and PD-L1 >50%.



Stratified by PS(0 or 1), histology (squamous or nonsquamous), and region (East Asian or non–East Asian enrollment). Crossover allowed Powered for RR, PFS and OS BICR and Investigator Review



Keynote 024- Immuno versus Chemotherapy Five-Year Outcomes






Reck et al. J Clin Oncol 39:2339, 2021

ChemoImmunotherapy versus Chemotherapy

n Analysis of Overall Su




Subgroup	No. of Events/ No. of Patients	Hazard Ratio for Deat	th (95% CI)
Overall	235/616		0.49 (0.38-0.64
Age			
<65 yr	133/312	_	0.43 (0.31-0.61
≥65 yr	102/304		0.64 (0.43-0.95
Sex			
Male	143/363		0.70 (0.50-0.99
Female	92/253		0.29 (0.19-0.44
ECOG performance-status	score		
0	74/266		0.44 (0.28-0.71
1	159/346		0.53 (0.39-0.73
Smoking status			
Current or former	211/543		0.54 (0.41-0.71
Never	24/73		0.23 (0.10-0.54
Brain metastases at baselin	e		
Yes	51/108	_	0.36 (0.20-0.62
No	184/508		0.53 (0.39-0.71
PD-L1 tumor proportion sco	ore		
<1%	84/190		0.59 (0.38-0.92
≥1%	135/388		0.47 (0.34-0.66
1-49%	65/186		0.55 (0.34-0.90
≥50%	70/202		0.42 (0.26-0.68
Platinum-based drug			
Carboplatin	176/445		0.52 (0.39-0.71
Cisplatin	59/171		0.41 (0.24-0.69
		0.1 1	.0
		Pembrolizumab Combination Better	Placebo Combination Better

N=616 in 2:1 randomization ORR 47% versus 19%.

Gandhi et al. N Engl J Med 2018;378:2078-92.



Dual Immuno versus Chemotherapy Nivolumab/Ipilimumab




limumab 583 506 437 384 354 312 277 245 226 214 188 125 60 17 3 0 583 522 441 357 310 264 228 190 167 147 122 76 34 11 1 0

> BMS 227 6-arm randomization NivIpi=583, included 30% Sq RR35.9%



Hellman et al. N Engl J Med 381;21 11/21/19.

USA Cancer Mortality over Time



1965- Surgeon General Smoking 1991-2018- 31% decline USA Mortality Lung CA is half of decline 2014-18



Radon-Induced Lung Cancer

- Radon is a noble gas naturally produced environmentally through uranium decay that releases *alpha*, beta, and gamma radiation.
- Models of Chronic exposure of inhaled radon support radon as the #2 cause of lung cancer
- Currently, there is no clinical way to identify patients with radon-induced lung cancer.



EPA/CD C


Radiation and Cancer















Radon Occupational Studies

- **BEIR VI** (Biologic Effects of Ionizing Radiation)
 - 11 studies of miners and lung cancer
 - 68,000 miners, 1.2 million person-years
 - 2700 cancer deaths
 - Lung cancer proportional to radon exposure
 - Cigarette smoking interaction
 - Subset @ EPA level = 4 pCi/l same result



National Research Council. Health effects of exposure to Radon :

BEIR VI. National Academy Press 1999.

Lubin. Environmental factors in cancer: radon. Rev Envir Health 2010

Radon Residential Studies


- 22 case control studies
 - China (2), Europe (13), North America (7)
- 19/22 increase lung cancer risk at 2.7pCi/l
 China 1.13, EU 1.08, No America 1.11
- If effect is seen at 2.7, then risk is underestimated!



Darby. Residential radon and lung cancer-detailed result of a collaborative analysis of 7148 persons with lung cancer and 14208 without lung cancer from 13 epidemiological studies in Europe.

Scand J Work Environ Health 32:1-84, 2006

Radon Rat Model of Lung Cancer



1574 rats exposed to radon through rebreathing system. WLM (working level months)

Cumulative exposure more important than dose rate



Collier et al. Int. J. Radiat. Biol., 81:631, 2005.

What molecular type of Lung Cancer is Associated with Radon


- Studies in Never smokers
- Rauvina Spain 2016
- Mezquita France 2019
- Taga USA 2012

Inc radon in ALK(NS)Inc radon with mutation(NS)No association

Taga et. al. Cancer Epidemiol Biomarkers Prev; 21: 988. 2012



Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases



HUNTSMAN CANCER INSTITUTE

Ruano-Ravina et al. Eur Respir J 2016; 48: 1462

Molecular Alterations, Indoor Radon in lung cancer from the French National Cancer Registry


	Low risk	Intermediate	High	Р	
5055	1000 (100()	1000 (110())		0.0004	
EGFR mutation	1962 (10%)	4338 (11%)	4176 (11.4%)	<0.0001	
ALK rearrangement	577 (3.3%)	1019 (3%)	896 (3%)	0.35	
BRAF mutation	327 (1.8%)	830 (2.4%)	692 (2.4%)	0.0001	
HER2 mutation	109 (0.6%)	266 (0.9%)	252 (0.8%)	0.01	
ROS1	61 (0.9%)	133 (0.9%)	126 (1.3%)	0.005	
rearrangement					
KRAS mutation	4717 (29.8%)	9215 (28.2%)	7895 (27%)	<0.0001	
Molecular drivers*	3037 (3.9%)	6587 (4.4%)	6142 (4.4%)	<0.0001	
* EGFR, BRAF & HER2 mutations, ALK & ROS1 rearrangements; KRAS mutation excluded.					

Table 2: Prevalence of molecular alteration by radon risk area in France.

Mezquita et al. WLCC JTO Abstract 2019

What Kind of Lung Cancer is Associated with Radon

- My Bias-
- Radon is associated with all forms of Lung cancer and will show a large variety of mutations and have a gene signature that mimics radiation or smoking





Team Radon



Martin McMahon, PhD

Aria Vaishnavi, PhD

HUNTSMAN







Dani L. Dixon, PhD

Tony Hooker, PhD





Sonam Puri, MD Wallace Akerley, MD Matt Gumbleton, MD, PhD





Heidi Hanson, PhD Joemy Ramsay, PhD UNIVERSITY OF UTAH HUNTSMAN




Eric Gardner, PhD, PharmD


Harold Varmus, PhD



HCI Lung DOT Pilot Grant Workflow



Projected Timeline



UPDB:National Database

HCI is one of the best places in the world to study LCINS



Lung Cancer Summary

- Lung cancer is defined by
 - Microscope
 - DNA mutations panel,
 - Immune panel,
- Lung Cancer is many types of cancer
 - Smoker versus non-smoker
 - Few Actionable mutation versus Many
- Radon
 - Cause of lung cancer in smokers and never-smokers
 - Most important natural cause of cancer (preventable)
 - Awareness, Mitigation saves lives
 - We hope to define a radon signature

